Arduino has just announced the Arduino Matter Discovery Bundle (AKX00081), an all-in-one development kit designed to help ...

In October 2025, Protalix BioTherapeutics, Inc. (NYSE:PLX) announced that the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion regarding Chiesi’s request for four-week ...

The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026.

PLX-200 is an oral compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier and its established ...

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based ...

Protalix BioTherapeutics (PLX) said on Friday that an expert panel of the European Medicines Agency (EMA), endorsed a new dosing regimen for Elfabrio, an enzyme replacement therapy developed by the ...

After Qualcomm’s purchase of Arduino it has left many wondering what market its new Uno Q board is trying to target. Taking the ongoing RAM-pocalypse as inspiration, [Bringus Studios] made a tongue-in ...

Ever wanted to know how engineers made their calculations before digital calculators were on every workbench? [Richard ...

PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization ...

) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026. The price target is an average of many targets provided by analysts. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.